Drug Profile
Rasburicase
Alternative Names: Elitek; Fasturtec; Rasuritek; Recombinant urate oxidase - Sanofi-Aventis; SR 29142; Uricase - Sanofi-AventisLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Antigouts; Oxidoreductases
- Mechanism of Action Urate oxidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hyperuricaemia
Most Recent Events
- 14 Jul 2017 No recent reports on development identified - Registered for Hyperuricaemia (Chemotherapy-induced) in Iceland and Liechtenstein (IV,infusion)
- 06 Aug 2014 Rasburicase licensed to Emcure Pharmaceuticals in India
- 17 Oct 2009 Registered for Hyperuricaemia (Chemotherapy-induced) in USA (IV,infusion)